Comparative Pharmacology
Head-to-head clinical analysis: NAFAZAIR versus STERANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAFAZAIR versus STERANE.
NAFAZAIR vs STERANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown. It is a purified fatty acid derivative that may modulate inflammatory responses.
Sterane (prednisolone) is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
2.5 mg subcutaneously once daily.
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life is 6-8 hours; in moderate renal impairment (CrCl 30-50 mL/min) extends to 12-15 hours.
Terminal elimination half-life is approximately 2.5 hours (range 2-3 hours) in adults with normal renal function; clinically, this supports twice-daily dosing
Primarily renal excretion (70-80% as unchanged drug), with 15-20% fecal elimination via biliary secretion.
Renal (approximately 70% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 30%)
Category C
Category C
Intranasal Antihistamine/Corticosteroid
Corticosteroid